102 related articles for article (PubMed ID: 8278877)
21. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
[TBL] [Abstract][Full Text] [Related]
22. [Preliminary clinical evaluation of systemic chemotherapy of invasive cancer of the bladder by the CMV protocol].
Szymanowski J; Koźmińska E; Malewski A; Stokłosa A
Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):525-7. PubMed ID: 1282711
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup.
Dreicer R; Kollmorgen TA; Smith RF; Williams RD
J Urol; 1993 Sep; 150(3):849-52. PubMed ID: 8345598
[TBL] [Abstract][Full Text] [Related]
24. DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer.
Türkölmez K; Baltaci S; Bedük Y; Müftüoğlu YZ; Göğüş O
Scand J Urol Nephrol; 2002 Feb; 36(1):46-51. PubMed ID: 12002357
[TBL] [Abstract][Full Text] [Related]
25. M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.
Scher H; Herr H; Sternberg C; Fair W; Bosl G; Morse M; Sogani P; Watson R; Darshaw D; Reuter V
Prog Clin Biol Res; 1990; 353():179-86. PubMed ID: 2217417
[No Abstract] [Full Text] [Related]
26. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
27. [Postoperative adjuvant M-VAC chemotherapy for invasive bladder cancer].
Yamashita S; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Yushita Y; Sakuragi T
Hinyokika Kiyo; 1992 May; 38(5):519-24. PubMed ID: 1609658
[TBL] [Abstract][Full Text] [Related]
28. [Infiltrating tumors of the bladder. Local response to systemic platinum-based chemotherapy].
Boccon-Gibod L; Adjiman S; Beuzeboc P; Steg A
Ann Urol (Paris); 1989; 23(4):285-8. PubMed ID: 2686541
[TBL] [Abstract][Full Text] [Related]
29. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
Koch MO; Coussens D
Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
[No Abstract] [Full Text] [Related]
30. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder.
Keating JP; Zincke H; Hahn RG; Morgan WR
Prog Clin Biol Res; 1990; 353():119-27. PubMed ID: 2217409
[No Abstract] [Full Text] [Related]
31. [The M-VEC chemotherapy of advanced bladder tumors].
Kumanov Kh; Ormanov I; Tsvetkov M; Donovski L
Khirurgiia (Sofiia); 1989; 42(6):39-45. PubMed ID: 2634800
[TBL] [Abstract][Full Text] [Related]
32. [Neoadjuvant chemotherapy (M-VAC) for locally invasive bladder cancer].
Kamoto T; Kawakita M; Okabe T; Matsumoto M; Matsuda T; Yoshida O
Hinyokika Kiyo; 1992 Apr; 38(4):405-11. PubMed ID: 1529813
[TBL] [Abstract][Full Text] [Related]
33. [Neo-adjuvant M-VAC in the treatment of infiltrating bladder tumors].
García Reboll L; Vera Donoso CD; Ruíz Cerdá JL; Pontones Moreno JL; Martínez Jabaloyas JM; Jiménez Cruz JF
Actas Urol Esp; 1994 Apr; 18(4):271-6. PubMed ID: 7976712
[TBL] [Abstract][Full Text] [Related]
34. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
Hoch V; Noll F; Schreiter F
Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for bladder cancer.
Muñoz A; Barceló JR; López-Vivanco G
N Engl J Med; 2003 Dec; 349(23):2272-3; author reply 2272-3. PubMed ID: 14657442
[No Abstract] [Full Text] [Related]
36. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
[TBL] [Abstract][Full Text] [Related]
37. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
38. [Place of chemotherapy in the treatment of invasive bladder tumors].
Pariente JL; Theodore C; Davin JL; Rischmann P; Chopin D
Prog Urol; 1999 Apr; 9(2):219-24. PubMed ID: 10370944
[TBL] [Abstract][Full Text] [Related]
39. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
[TBL] [Abstract][Full Text] [Related]
40. Neo-adjuvant intra-arterial chemotherapy in locally advanced bladder cancer.
Chechile G; Montie J; Pontes JE; Bukowski RM
Prog Clin Biol Res; 1990; 353():153-61. PubMed ID: 2217413
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
